Summary
The provided claims are not prescribing-information claims (they concern branding/marketing, patents, generics/biosimilars, and litigation). No statements can be verified against the supplied ELIQUIS USPI excerpts (Warnings/Precautions, Dosage/Administration, Patient Counseling).
Category Scores
Accurate Statements
Unsupported Statements
Apixaban is marketed under the brand name Eliquis.
No support in the supplied ELIQUIS USPI excerpts (Warnings/Precautions 5.1, 5.3; Dosage/Administration 2.4; Patient Counseling 17).
Eliquis (apixaban) is marketed by Bristol-Myers Squibb (BMS) and Pfizer.
No support in the supplied ELIQUIS USPI excerpts.
Bristol-Myers Squibb and Pfizer formed a partnership in 2010 to co-market and co-develop apixaban.
No support in the supplied ELIQUIS USPI excerpts.
BMS and Pfizer hold patents for apixaban in several countries, including the United States, Europe, and Japan.
No support in the supplied ELIQUIS USPI excerpts.
The U.S. patent for apixaban is set to expire in 2025.
No support in the supplied ELIQUIS USPI excerpts.
Generic suppliers face regulatory hurdles in bringing apixaban to market due to the complexity of the patent environment and the need for regulatory approval.
No support in the supplied ELIQUIS USPI excerpts.
To develop generic versions of apixaban, companies must navigate the U.S. FDA approval process.
No support in the supplied ELIQUIS USPI excerpts.
The U.S. FDA approval process for generic apixaban involves demonstrating pharmacokinetic equivalence and safety.
No support in the supplied ELIQUIS USPI excerpts.
The approval pathway for biosimilars is separate from generic drugs.
No support in the supplied ELIQUIS USPI excerpts.
For biosimilars, the FDA requires demonstration of pharmacokinetic and pharmacodynamic equivalence to an approved reference product.
No support in the supplied ELIQUIS USPI excerpts.
The biosimilarity approval pathway may provide an alternative route for generic suppliers to enter the market.
No support in the supplied ELIQUIS USPI excerpts.
An ongoing patent dispute between BMS and Pfizer and other generic companies has been subject to litigation and regulatory review.
No support in the supplied ELIQUIS USPI excerpts.
The outcome of the litigation may impact the availability and pricing of generic versions of apixaban.
No support in the supplied ELIQUIS USPI excerpts.
Mylan and Sandoz have been involved in the development and marketing of apixaban.
No support in the supplied ELIQUIS USPI excerpts.
Contradictions
Important Omissions
No AI-generated prescribing-information content (indications, dosage, contraindications, boxed warnings, warnings/precautions, interactions, monitoring, administration, storage) was provided to audit against the label sections. The claims provided are non-label business/legal assertions.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
The statements do not address patient dosing, contraindications, warnings, or monitoring from the supplied ELIQUIS USPI excerpts; therefore, no direct patient-safety impact can be assessed from label alignment. However, the lack of on-label prescribing claims prevents a meaningful safety alignment audit.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
No On-Label Prescribing Claims Provided
Primary Issue
Claims are about branding/marketing, patents, and regulatory/legal process rather than FDA-approved prescribing information content (label). None of the supplied statements can be verified against the provided ELIQUIS USPI excerpts.
Suggested Improvement
Provide the specific AI-generated text that makes prescribing/label claims (e.g., indication, dosage regimen, contraindications, boxed warnings, warnings/precautions, drug interactions, monitoring, administration, storage). Then re-run the audit using those statements.